{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:11:41Z","timestamp":1786119101129,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1097\/ftd.0b013e318194767d","type":"journal-article","created":{"date-parts":[[2009,1,20]],"date-time":"2009-01-20T03:38:43Z","timestamp":1232422723000},"page":"86-94","source":"Crossref","is-referenced-by-count":19,"title":["A Population Pharmacokinetic Model of Gabapentin Developed in Nonparametric Adaptive Grid and Nonlinear Mixed Effects Modeling"],"prefix":"10.1097","volume":"31","author":[{"given":"Kristin C","family":"Carlsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margunn van de","family":"Schootbrugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi Oien","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica Ratti","family":"Moberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats O","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Ove","family":"Hoem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210129","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.280.21.1837","article-title":"Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.","volume":"280","author":"Rowbotham","year":"1998","journal-title":"JAMA"},{"key":"R2-10-20210129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0304-3959(02)00255-5","article-title":"Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial.","volume":"99","author":"Serpell","year":"2002","journal-title":"Pain"},{"key":"R3-10-20210129","first-page":"830","article-title":"Pharmacokinetics and metabolism of gabapentin in rat, dog and man.","volume":"36","author":"Vollmer","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"R4-10-20210129","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00003495-199346030-00007","article-title":"Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy.","volume":"46","author":"Goa","year":"1993","journal-title":"Drugs"},{"key":"R6-10-20210129","first-page":"S17","article-title":"Clinical pharmacokinetics of gabapentin.","volume":"44","author":"McLean","year":"1994","journal-title":"Neurology"},{"key":"R7-10-20210129","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1023\/A:1018951214146","article-title":"A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma.","volume":"10","author":"Stewart","year":"1993","journal-title":"Pharm Res"},{"key":"R8-10-20210129","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/01616412.1999.11740975","article-title":"Saturable transport of gabapentin at the blood-brain barrier.","volume":"21","author":"Luer","year":"1999","journal-title":"Neurol Res"},{"key":"R9-10-20210129","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1059131102001425","article-title":"The absorption of gabapentin following high dose escalation.","volume":"12","author":"Berry","year":"2003","journal-title":"Seizure"},{"key":"R10-10-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0920-1211(97)00078-8","article-title":"High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients.","volume":"29","author":"Wilson","year":"1998","journal-title":"Epilepsy Res"},{"key":"R11-10-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0920-1211(98)00020-5","article-title":"Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy.","volume":"31","author":"Gidal","year":"1998","journal-title":"Epilepsy Res"},{"key":"R12-10-20210129","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1023\/B:PHAM.0000003371.32474.ee","article-title":"The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.","volume":"20","author":"Lockwood","year":"2003","journal-title":"Pharm Res"},{"key":"R13-10-20210129","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","article-title":"Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability.","volume":"40","author":"Gidal","year":"2000","journal-title":"Epilepsy Res"},{"key":"R14-10-20210129","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0731-7085(03)00572-7","article-title":"Sample preparation and determination of gabapentin in venous and capillary blood using liquid chromatography-tandem mass spectrometry.","volume":"34","author":"Carlsson","year":"2004","journal-title":"J Pharm Biomed Anal"},{"key":"R15-10-20210129","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Methods Programs Biomed"},{"key":"R16-10-20210129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/B:JOPA.0000029490.76908.0c","article-title":"A Bayesian approach to tracking patients having changing pharmacokinetic parameters.","volume":"31","author":"Bayard","year":"2004","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R17-10-20210129","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1023\/A:1011968129921","article-title":"Coverage and precision of confidence intervals for area under the curve using parametric and non-parametric methods in a toxicokinetic experimental design.","volume":"15","author":"Bonate","year":"1998","journal-title":"Pharm Res"},{"key":"R18-10-20210129","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/FTD.0b013e318161a38c","article-title":"Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery.","volume":"30","author":"Macdonald","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R19-10-20210129","first-page":"196","article-title":"Pharmacokinetics of gabapentin in patients treated with phenytoin.","volume":"9","author":"Graves","year":"1989","journal-title":"Pharmacotherapy"},{"key":"R21-10-20210129","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R22-10-20210129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1191\/0269216304pm845ra","article-title":"Gabapentin in the treatment of neuropathic pain.","volume":"18","author":"Bennett","year":"2004","journal-title":"Palliat Med"},{"key":"R23-10-20210129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjopharm.2004.09.004","article-title":"Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia.","volume":"2","author":"Parsons","year":"2004","journal-title":"Am J Geriatr Pharmacother"},{"key":"R24-10-20210129","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1528-1157.1998.tb01357.x","article-title":"Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy.","volume":"39","author":"Beydoun","year":"1998","journal-title":"Epilepsia"},{"key":"R25-10-20210129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1059-1311(98)90009-7","article-title":"Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group.","volume":"7","author":"Baulac","year":"1998","journal-title":"Seizure"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e318194767d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:30:34Z","timestamp":1786037434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-200902000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318194767d","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}